KYNTRA BIO, INC.
KYNBKyntra Bio, Inc. (formerly FibroGen, Inc.) is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
Drugs in Pipeline
10
Phase 3 Programs
5
Upcoming Catalysts
1
Next Catalyst
Aug 10, 2026
6dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
KYNB Earnings Report
EPS Est: $-3.27 | FQ end 2026-06
How KYNB's past catalysts played out
Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
Pancreatic Cancer Non-resectable
Epoetin Alfa
Anemia in End Stage Renal Disease
SEPO®
Chemotherapy Induced Anemia
Roxadustat
Anemia Associated With End Stage Renal Disease (ESRD)
FG-4592
Anemia
FG-3019
Idiopathic Pulmonary Fibrosis
Pamrevlumab
Idiopathic Pulmonary Fibrosis
FG2216
Renal Anemia
Oral Iron
Dialysis
FG-3246
Metastatic Castration-Resistant Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX | Phase 3 | Pancreatic Cancer Non-resectable | - | - |
Epoetin Alfa | Phase 3 | Anemia in End Stage Renal Disease | - | - |
SEPO® | Phase 3 | Chemotherapy Induced Anemia | - | - |
Roxadustat | Phase 3 | Anemia Associated With End Stage Renal Disease (ESRD) | - | - |
FG-4592 | Phase 3 | Anemia | - | - |
FG-3019 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
Pamrevlumab | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
FG2216 | Phase 2 | Renal Anemia | - | - |
Oral Iron | Phase 2 | Dialysis | - | - |
FG-3246 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in KYNTRA BIO, INC.'s drug pipeline?→
CatalystAlert tracks 10 drug candidates in KYNTRA BIO, INC.'s (KYNB) pipeline across Phase 3, Phase 2. Its lead program is Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is KYNTRA BIO, INC.'s next FDA catalyst?→
KYNTRA BIO, INC.'s (KYNB) next tracked catalyst is a Earnings expected August 10, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KYNB biotech catalysts?→
Add KYNB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow KYNTRA BIO, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.